Cryo-Cell International, Inc. (CCEL)

NYSEAMERICAN: CCEL · USD

$5.05

-0.30 (-5.6%)· Recorded snapshot

Market cap	40.7M
Revenue (ttm)	31.1M
Net income (ttm)	-1.9M
EPS (ttm)	-$0.24
Shares out	8.1M
P/E (forward)	63.1x
Volume	6,522.99
Beta	0.59

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 31.1M
Net income (ttm): -1.9M
EPS (ttm): -$0.24
P/E (forward): 63.1x
Market cap: 40.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/E63.1

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC0.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CCEL indicators

Market & fundamental data

Available fields

250

Groups with data

Currency

USD

Showing 250 of 250 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000862692
Company name	Cryo-Cell International, Inc.
Country	United States
Country code	US
CUSIP number	228895108
Earnings date	2026-10-09
Earnings time	amc
Employees	76
Employees change	-10
Employees growth	-11.63%
Enterprise value	$45.3M
Exchange	NYSEAMERICAN
Financial currency	USD
Financial report date	2026-08-31
First seen	2026-05-09
Fiscal year end	November
Founded	1989
Industry	Medical Care Facilities
IPO date	1997-01-21
Is primary listing	Yes
Is SPAC	No
ISIN number	US2288951088
Last 10-K release date	2026-02-27
Last earnings date	2026-10-09
Last refreshed	2026-11-04
Last stock split type	Never
Market cap	$40.7M
Market cap category	Nano-Cap
Options	No
Price	$5.05
Price currency	USD
Sector	Healthcare
SIC code	8090
Stock price date	2026-11-03
Symbol	CCEL
U.S. state	Florida
Website	https://www.cryo-cell.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-4.79%
EV/EBIT	239.17x
EV/EBITDA	39.03x
EV/FCF	9.74x
EV/Sales	1.46x
FCF / EV yield	10.27%
FCF yield	11.42%
Forward EV/Sales	1.57x
Forward P/E	63.13x
Forward P/S	1.41x
Industry forward P/E	15.46x
Industry P/E	17.9x
P/(FCF - SBC) ratio	9.49x
P/(OCF - SBC) ratio	8.93x
P/FCF ratio	8.75x
P/OCF ratio	8.28x
P/S ratio	1.31x
Price/EBITDA ratio	35.08x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	0.61%
EBITDA margin	3.73%
FCF margin	14.94%
Gross margin	64.53%
Operating margin	0.61%
Pretax margin	-6.13%
Profit margin	-6.25%
Profit per employee	$-25,595
Profitable quarters	3
Revenue per employee	$409,560
ROA	0.19%
ROA (5Y)	2.44%
ROCE	0.4%
ROIC	0.41%
SBC / revenue	1.15%
Tax / revenue	0.12%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (Q)	75.09%
EPS growth (QoQ)	128.89%
EPS growth quarters	2
EPS growth years	0
FCF growth	-24.77%
FCF growth (Q)	-58.37%
FCF growth (QoQ)	-42.65%
FCF growth 3Y	16.97%
FCF growth 5Y	-9.43%
Gross profit growth	-17.9%
Gross profit growth (Q)	3.1%
Gross profit growth 3Y	-4.03%
Gross profit growth 5Y	1.31%
Net income growth (Q)	69.53%
Net income growth (QoQ)	129.09%
Net income growth quarters	2
Net income growth years	0
OCF growth	-22.57%
OCF growth (Q)	-54.99%
OCF growth (QoQ)	-38.15%
OCF growth 10Y	1.09%
OCF growth 3Y	-14.98%
OCF growth 5Y	-11.83%
Operating income growth	-95.62%
Operating income growth (Q)	15.43%
Operating income growth 3Y	-64.92%
Operating income growth 5Y	-47.24%
Revenue growth	-1.96%
Revenue growth (Q)	-0.02%
Revenue growth (QoQ)	0.62%
Revenue growth 10Y	3.05%
Revenue growth 3Y	-0.11%
Revenue growth 5Y	1.35%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-268,871
Depreciation and amortization	$971,385
EBIT	$189,419
EBITDA	$1.2M
EPS	$-0.24
FCF per share	$0.58
Financing cash flow	$-3.3M
Free cash flow	$4.7M
Free cash flow minus SBC	$4.3M
Gross profit	$20.1M
Income taxes	$36,817
Investing cash flow	$-416,257
Net borrowing	$-3.4M
Net cash flow	$1.2M
Net income	$-1.9M
Operating cash flow minus SBC	$4.6M
Operating income	$189,419
Revenue	$31.1M
Stock-based compensation	$358,870

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-0.12
Book value per share	$-2.03
Debt / EBITDA	5.42
Debt / FCF	1.9
Goodwill	$1.9M
Interest coverage	0.1
Long-term assets	$49.1M
Long-term liabilities	$63.4M
Net cash (debt)	$-4.6M
Net cash / market cap	-11.27%
Net debt / EBITDA	3.95
Net debt / FCF	0.99
Piotroski F-Score	5
Property, plant and equipment	$21.1M
Shareholders' equity	$-16.4M
Tangible book value	$-19.2M
Tangible book value per share	$-2.38
Total assets	$62.3M
Total cash	$4.2M
Total debt	$8.8M
Total liabilities	$78.7M
WACC	9.07%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.5
Current assets	$13.2M
Current liabilities	$15.3M
Current ratio	0.86
Inventory turnover	18.57
Net working capital	$-5.8M
Quick ratio	0.72
Working capital	$-2.2M
Working capital turnover	-6.96

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.18%
Dividend growth years	1
Dividend payment date	2025-05-30
Dividend payment years	2
Dividend per share	$0.00
Dividend yield	0%
Last dividend	$0.15
Shareholder yield	0.18%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	31.51%
10Y return CAGR	5.07%
10Y total return	63.96%
150-day SMA	$3.83
15Y price change	165.79%
15Y return CAGR	8.31%
15Y total return	231.37%
1D price change	-5.61%
1M price change	26.57%
1M total return	26.57%
1W price change	1.82%
1W total return	1.82%
1Y price change	11.97%
1Y return CAGR	11.98%
1Y total return	11.97%
20-day SMA	$4.62
200-day SMA	$3.70
20Y price change	108.68%
20Y return CAGR	4.9%
20Y total return	160.17%
3M price change	47.66%
3M total return	47.66%
3Y price change	-1.17%
3Y return CAGR	2.65%
3Y total return	8.17%
50-day SMA	$4.34
50-day SMA vs 200-day SMA	50over200
52-week high	$5.45
52-week high date	2026-10-29
52-week low	$2.72
52-week low date	2026-03-25
5Y price change	-59.54%
5Y return CAGR	-12.79%
5Y total return	-49.55%
6M price change	44.29%
6M total return	44.29%
All-time high	$14.16
All-time high date	2021-09-02
All-time low	$0.30
All-time low date	2003-07-24
Average true range (ATR)	$0.40
Average volume	12.9K
Beta (1Y)	0.79
Beta (2Y)	0.26
Beta (5Y)	0.59
Change from 52-week high	-7.25%
Change from 52-week low	85.66%
Change from all-time high	-64.34%
Change from all-time low	1,583.33%
Change from open	1%
Day's gap	-6.54%
Dollar volume	$32,941
High price	$5.35
Low price	$5.00
Monthly RSI	52.65
Open price	$5.00
Position in 52-week range	14.29%
Previous close	$5.35
Price vs 150-day SMA	31.78%
Price vs 20-day SMA	9.33%
Price vs 200-day SMA	36.6%
Price vs 50-day SMA	16.47%
Relative volume	0.5
RSI	58.77
Sharpe ratio	0.48
Sharpe ratio (3Y)	0.36
Sharpe ratio (5Y)	0.09
Sortino ratio	0.78
Sortino ratio (3Y)	0.63
Sortino ratio (5Y)	0.23
Volume	6.5K
Weekly RSI	65.08
YTD price change	46.8%
YTD total return	46.81%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	4.1M
Float percentage	51.09%
Shares change (QoQ)	0.12%
Shares change (YoY)	-0.18%
Shares held by insiders	39.35%
Shares held by institutions	6.89%
Shares outstanding	8.1M
Short % of float	0.23%
Short % of shares	0.12%
Short ratio	0.5 days

Deeper analysis on CCEL

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CCEL report

Is a complete CCEL research report available?

No complete published report is available for Cryo-Cell International, Inc. (CCEL) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Cryo-Cell International, Inc. (CCEL)

Price

Financial snapshot

Fair-value bridge

Latest news · CCEL

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CCEL indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CCEL

Frequently asked questions